Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

被引：328

作者：

Ettinger, B

San Martin, J

Crans, G

Pavo, I

机构：

[1] Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA

[2] Eli Lilly & Co, Indianapolis, IN 46285 USA

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 2004年 / 19卷 / 05期

关键词：

osteoporosis; parathyroid hormone; bisphosphonates; selective estrogen receptor modulators;

D O I：

10.1359/JBMR.040117

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We investigated the effects of 18 months of treatment with teriparatide in patients previously treated with long-term antiresorptive therapy using bone turnover markers and bone densitometry. Previous raloxifene treatment allowed for teriparatide-induced early bone marker and BMD increases comparable with previously published results for treatment-naive patients. Conversely, previous alendronate treatment reduced the bone marker and BMD response.

引用

页码：745 / 751

页数：7

共 27 条

[1] The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
Black, DM
Greenspan, SL
Ensrud, KE
Palermo, L
McGowan, JA
Lang, TF
Garnero, P
Bouxsein, ML
Bilezikian, JP
Rosen, CJ
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) : 1207 - 1215
[2] Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women
Boivin, GY
Chavassieux, PM
Santora, AC
Yates, J
Meunier, PJ
[J]. BONE, 2000, 27 (05) : 687 - 694
[3] Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis
Chavassieux, PM
Arlot, ME
Reda, C
Wei, L
Yates, AJ
Meunier, PJ
[J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (06) : 1475 - 1480
[4] Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal
Cosman, F
Nieves, J
Woelfert, L
Formica, C
Gordon, S
Shen, V
Lindsay, R
[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (05) : 925 - 931
[5] Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women
Cosman, F
Nieves, J
Woelfert, L
Shen, V
Lindsay, R
[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (06) : 1051 - 1055
[6] Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis:: A paired biopsy study
Dempster, DW
Cosman, F
Kurland, ES
Zhou, H
Nieves, J
Woelfert, L
Shane, E
Plavetic, K
Müller, R
Bilezikian, J
Lindsay, R
[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (10) : 1846 - 1853
[7] EVIDENCE THAT INTERMITTENT TREATMENT WITH PARATHYROID-HORMONE INCREASES BONE-FORMATION IN ADULT-RATS BY ACTIVATION OF BONE LINING CELLS
DOBNIG, H
TURNER, RT
[J]. ENDOCRINOLOGY, 1995, 136 (08) : 3632 - 3638
[8] Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene -: Results from a 3-year randomized clinical trial
Ettinger, B
Black, DM
Mitlak, BH
Knickerbocker, RK
Nickelsen, T
Genant, HK
Christiansen, C
Delmas, PD
Zanchetta, JR
Stakkestad, J
Glüer, CC
Krueger, K
Cohen, FJ
Eckert, S
Ensrud, KE
Avioli, LV
Lips, P
Cummings, SR
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07): : 637 - 645
[9] The effects of parathyroid hormone, alendronate, or both in men with osteoporosis
Finkelstein, JS
Hayes, A
Hunzelman, JL
Wyland, JJ
Lee, H
Neer, RM
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) : 1216 - 1226
[10] Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34) - A randomized controlled trial
Finkelstein, JS
Klibanski, A
Arnold, AL
Toth, TL
Hornstein, MD
Neer, RM
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (12): : 1067 - 1073

← 1 2 3 →